Treatment of small resting B cells with soluble F(ab')2 fragments of anti-IgM, an analogue of T-independent type 2 antigens, induced activation characterized by proliferation and the expression of surface CD5. In 
tein displayed elevated levels of CD23 (FcJII receptor) and no surface CD5. Treatment with anti-IgM and CD40L induced higher levels of proliferation and generated a single population of B cells coexpressing minimal amounts of CD5 and only a slight elevation of CD23. Anti-IgM-but not CD40L-mediated activation was highly sensitive to inhibition by cyclosporin A and FK520. Sp-cAMPS, an analogue of cAMP, augmented CD40L and suppressed surface IgM-mediated activation. Taken together these results are interpreted to mean that there is a single population of small resting B cells that can respond"to either T-independent type 2 (surface IgM)-or T-dependent (CD40)-mediated activation. In response to different intracellular signals these cells are induced to enter alternative differentiation pathways.
Though it has been suggested that T-cell-independent (TI) and thymus-dependent (TD) responses (1) might be generated from different B-cell precursors (2) , the weight of evidence suggests that a given B cell can enter either the TI or TD pathway (3) (4) (5) . We wanted to directly determine if B cells exist as two precursor populations or if there is a single population that can be induced to enter alternative differentiation pathways. If the latter proved to be the case, we wanted to determine if the minimal inductive events were sufficient to induce phenotypic differences in responding cells. To study this we chose to use anti-IgM antibody as an experimental analogue of one type of TI antigen. TI antigens are divided into type 1, which are intrinsically mitogenic [such as lipopolysaccharide (LPS) in the mouse], and type 2, which are nonmitogenic repeating unit molecules such as polysaccharides or their haptenated derivatives (6) . TI-2 activation is initiated by the crosslinking of surface immunoglobulin (slg) followed by a cascade of events that includes cytoplasmic tyrosine kinases, a Ca2+ flux, and the catalytic activity of protein kinase C (PKC) (reviewed in ref. 7) . The F(ab')2 fragments of antibody to mouse 1gM can bind to B-cell sIgM so as to effect its crosslinking and thereby can provide a polyclonal B-cell activating signal equivalent to a TI-2 antigen (8) .
Unlike TI-2 responses, a TD response does not require sIg crosslinking, as even monomeric antigen can be bound, endocytosed, processed, and presented in the context of major histocompatibility complex class II for T-helper cell recognition and activation followed ultimately by T-cell-mediated activation of B cells (9) . The crucial TD signal is provided by
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direct contact with an activated T-helper cell such that the surface molecule gp39 [CD40 ligand (CD40L)] of the T cell ligates the CD40 of the B cell (10) .
Our strategy to determine if minimal TD and TI-2 signals were sufficient to induce phenotypic differences in B cells was to use an antigen that could be modified so as to initiate either a TD or a TI-2 response. To produce a TD response we used monovalent Fab of rabbit anti-IgM and provided help in the form of the clone CDC35, a T-helper 2 line known to provide help to B cells that have bound, processed, and presented rabbit Fab in the context of IAd (9, 11) . To provide the equivalent of a TI-2 signal we used the divalent F(ab')2 form of the same antibody. We then compared the surface phenotypes of the responding B cells.
We followed up these initial experiments with others using fixed, preactivated helper T cells as B-cell activators (12 (14) .
Cells. Cells of the T-helper 2 line CDC35 were used 2-3 weeks after their last stimulation. B cells were partially purified as described (15) . Activated CDC35 T cells were generated by incubating cells at 1 x 106 per ml for 24 hr on plates precoated with anti-CD3 (145-2C11). The activated cells were then washed three times in phosphate-buffered saline and fixed with 0.4% fresh paraformaldehyde for 5 min (12) . Fixed cells were kept in tissue culture medium at 4°C. The supernate generated by these activated T cells was harvested and stored frozen.
B-Cell Culture and Stimulation. Cells were cultured in RPMI 1640 medium supplemented as described (15) . A polyclonal rabbit anti-mouse IgM was prepared as Fab and F(ab')2 fragments as described (9 104E, TEPC-183). By a Limulus amebocyte lysate method (Associates of Cape Cod) the levels of endotoxin were -10 ng per 30 ,ug of F(ab')2 for goat anti-mouse and rabbit anti-mouse preparations. Cells producing the fusion protein CD40L-CD8 (13) were from Peter Lane (Basel Institute for Immunology). Supernate containing recombinant CD40L produced optimal proliferation when used at a final dilution of 1:2. For thymidine incorporation cells were cultured in 96-microwell plates in 200 ,ul of medium. For cytometric analysis the cells were cultured in bulk. In both cases they were established at a density of 1 x 106 per ml. Fresh or fixed T cells were added at 1 x 106 cells per ml. Fresh T cells were irradiated to a total dose of 3600 rads (1 rad = 0.01 Gy) from a cesium source before being placed in culture with the B cells. K235 LPS was used at a concentration of 5 ,ug/ml. FK520 (L-683,590), rapamycin (L-657,862), and L-685,818 were kind gifts from Merck that were stored as 1 mg/ml stock solutions in ethanol. Cyclosporin A (CsA) (Sandoz Pharmaceutical) was stored at 2 mg/ml in 71.5% ethanol/28.5% Tween 80. Sp-cAMPS was purchased from Research Biochemicals (Natick, MA).
Flow Cytometry. Cultures containing CDC35 T cells were treated with anti-CD4 plus complement before staining. In some experiments living cells were enriched by centrifugation over a Ficoll gradient (Lympholyte-M, Cedarlane Laboratories) prior to staining. Cells were stained as described (15) . Flow cytometry data were obtained on a FACScan using LYSIS acquisition and analytic software (Becton Dickinson).
RESULTS
We first asked whether the surface phenotype Table 1 ), cell enlargement, and increased levels of surface CD44 ( Fig. 1) , events previously described in association with lymphocyte activation (15) . Culture with Fab or T cells alone did not induce proliferation (Table 1) , nor was any change in B-cell surface CD5 or CD23 seen (data not shown). F(ab')2-treated cells became CD5+ and showed no change in CD23 levels ( Fig.  1 ). The T cell plus Fab-stimulated cells neither became CD5+ nor had increased CD23 (Fig. 1) ; in fact, CD23 expression went down. Therefore, in response to TI-2 and TD antigens, B cells acquire different surface phenotypes. Previous experiments indicated that the CD23 levels of activated B cells could be lowered in response to interleukin 6 (IL-6) or increased by IL-4 treatment (15) . To determine if the changes in B cells activated by T-helper cells resulted only from direct contact with T-cell membranes or were dependent in whole or in part on antigen ligation and/or soluble ILs, we cultured B cells with fixed activated CDC35 cells. In the absence of any additional antigen they also induced proliferation (Table 1 , experiments J-180 and J-181), enlargement, and increased CD44 (Fig. 2) . As before, B cells activated by contact with activated T-helper cells did not express CD5 but they now showed increased levels of CD23 (Fig. 2) (Table 1) and lowered CD23 levels (Fig. 2) .
Next we asked whether ligation of CD40 by gp39, the CD40L on activated T-helper cell membranes (10), was sufficient to produce any of these changes in B cells. We consistently found that CD40L in the form of a soluble fusion molecule (CD40L-CD8) induced proliferation and an increase in cell size and increased surface CD44 and CD23 expression without altering CD5 levels (Table 1 and Fig. 3) . Therefore the signals generated by crosslinking sIgM on the one hand and ligation of CD40 on the other are sufficient to induce different activated B-cell phenotypes.
We considered the possibility that the CD5+ CD23 medium cells on the one hand and the CD5-CD23 high B cells on the other might represent two populations arising from different precursors. To test this possibility we cultured B cells with a combination of CD40L and F(ab')2. The cells responded by incorporating even higher levels of thymidine (Table 1) (Fig. 4) , consistent with there being a single population of multipotential precursors. If some B cells could respond only to slg crosslinking, while others could respond only to CD40 ligation, then two populations of activated cells should have been generated: CD5+ CD23 medium and CD5-CD23hi.
In a similar experiment, we cultured B cells with F(ab')2 (rather than Fab) together with T cells. In this situation only 11% of the B cells became CD5+ while cells cultured with F(ab')2 in the absence of T-helper cells were 56% CD5+. This supports the notion that simultaneous TD-and TI-2-type stimulation causes modulation of the induction of CD5. CD23 levels were low on all B cells in cultures with T cells, but because activated T-cell supernate is sufficient to downmodulate CD23 induction, this observation does not provide information on the possible effects of sIg ligation on the induction of CD23. We wished to determine if CD40L and sIg-induced B-cell signaling utilized precisely the same elements (7) . To test this we took advantage of the fact that anti-IgM activation can be blocked by the immunosuppressants CsA and FK520 (16) . These agents have many effects, but their ability to immunosuppress T cells is contingent on their binding to one of several proteins known collectively as immunophilins (16, 17 (18) . The phosphatase activity of calcineurin is required for the transport into the nucleus of several transcription factors, most particularly NFAT, required for expression of IL-2 and IL-4 (19, 20) . Although not characterized in such detail, in B cells the actions of these immunosuppressants appear to involve similar mechanisms. Fig. 5 shows that CsA and FK520 blocked anti-IgM-induced thymidine incorporation but that CD40L-induced proliferation was relatively insensitive to these drugs.
To determine if this immunosuppression required binding to an immunophilin we performed an experiment using the FK520 analogue L685,818. This molecule behaves as an antagonist of FK520 by competing for binding sites on FK506 binding protein (FKBP) forming a complex that does not inhibit calcineurin (21) . Unlike FK520, CsA binds to cyclophilin molecules, immunophilins that do not bind L685,818 (22) . Thus, if activation is blocked by binding of drug to immunophilins, then CsA, but not FK520, should suppress B cells in the presence of L685,818. We observed that in the presence of L685,818 CsA blocked the thymidine uptake induced by anti-IgM but FK520 did not (Fig. 5) .
As a second test of possible differences in the signal pathways activated by slg and CD40 we asked whether addition of Sp-cAMPS, a potent membrane-permeab logue (23), would differentially affect activ; Concentrations of Sp-cAMPS that inhibited a tion had the effect of augmenting CD40L-med (Fig. 6) . 
DISCUSSION
Ple cAMP anaKlaus (2) showed that CsA inhibits B-cell production Qf ation (24, 25 established that T-cell-dependent activation did not require sIg crosslinking (9) , although in itself this did not show that the signal pathways were different. Then it was shown that the activation through membrane immunoglobulin was more sensitive to the depletion of PKC by phorbol esters than that induced by fixed, activated T-helper cells (12, 25) . Experiments to demonstrate the relative dependency of anti-Ig and T-helper membranes on PKC and PKA enzymes have generated contradictory results (12, (25) (26) (27) . The sIg response appears to be PKC dependent and PKA independent, while the CD40 response is PKC independent. In any case, since these inhibitors (24, 25) , but this is not of three similar a uniform finding (27 Our results establish that the minimum activating inducers are sufficient to induce differences in B-cell phenotypes. The significance of the induction of CD5 expression after TI-2 activation of B cells is not known. This molecule is found on all mature T cells and a limited population of B cells, the so-called B-la subset (32) , and appears to be associated with the T-cell receptor (TCR) (33) and B-cell receptor (34) . Yet, a recent report suggests that mice expressing a CD5 deletion mutant had no defect in immune responses (35) , although the authors raised the possibility that lack of CD5 expression might increase thymocyte responses to TCR stimulation. The origin of CD5+ B cells is a matter of controversy; some investigators believe that they derive from a precommitted pool of fetal/ neonatal precursors (32) . Others, including ourselves, believe that any naive [newly differentiated, "B-0" (36)] B cell can become CD5+ as a consequence of sIgM ligation (37, 38) .
CD23, the low-affinity receptor for the Fc of IgE (Fc£RII), is a 45-kDa surface glycoprotein found on hematopoietic and follicular dendritic cells (39) but limited to the B-2 population of B cells (40) . Up-regulation of CD23 occurs in mice and humans following CD40 ligation by specific antibody or ligand (28, [41] [42] [43] . Although CD23 is up-regulated on previously activated B cells by IL-4, it is not expressed on recently activated B cells within germinal centers (39) , perhaps as a consequence of IL-6 activity (15). Interestingly, IL-4, an inducer of CD23, suppresses CD5 (44) (45) (46) (47) , and, as shown here, CD40 ligation, another inducer of high levels of CD23, also down-modulates the induction of CD5 by antiIgM. Thus the reciprocal induction of CD5 and CD23 on B cells appears to be a general characteristic of normal B-cell signaling.
Previously it was suggested that a generally held view of B-cell activation, that antigen-mediated slg crosslinking is a necessary first step for TD activation (48), may not be true (9) . We now propose that the quality of the initial activation event may commit a B cell to a particular differentiation pathway and a distinct set of functions.
